Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 14/20 | 0.44 |
| ▸ | CA1 | P00915 | 14/20 | 0.44 |
| ▸ | CA2 | P00918 | 14/20 | 0.44 |
| ▸ | CA9 | Q16790 | 14/20 | 0.44 |
| ▸ | CA6 | P23280 | 8/20 | 0.44 |
| ▸ | CA5A | P35218 | 8/20 | 0.44 |
| ▸ | CA7 | P43166 | 8/20 | 0.44 |
| ▸ | CA4 | P22748 | 7/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 7/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 7/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL945673 | 0.83 | G6PD (0.36) | CA12CA1CA2CA9CA6 | |
| SCHEMBL18191688 | 0.81 | NOS3 (0.46) | CA12CA1CA2CA9CA6 | |
| SCHEMBL2552895 | 0.76 | TXNRD1 (0.33) | — | |
| SCHEMBL13678715 | 0.75 | CA2 (0.37) | CA12CA1CA2CA9CA6 | |
| SCHEMBL5623673 | 0.72 | CA12 (0.41) | CA12CA1CA2CA9CA6 | |
| SCHEMBL21244899 | 0.69 | CA2 (0.38) | CA12CA1CA2CA9CA6 | |
| SCHEMBL6449500 | 0.68 | SLC40A1 (0.47) | CA12CA1CA2CA9CA6 | |
| SCHEMBL1653770 | 0.67 | — | — | |
| SCHEMBL31105996 | 0.67 | — | — | |
| SCHEMBL318097 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | PFIZER LIMITED | 2009-10-22 | — | — | US | disclosed |
| US-7273863-B1 | Benzophenones as inhibitors of reverse transcriptase | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-25 | — | — | US | disclosed |
| EP-1831157-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | Pfizer Limited (GB) | 2007-09-12 | — | — | EP | disclosed |
| EP-1710238-A1 | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LIMITED (GB) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006067587-A2 | NONNUCLEOSIDE INHIBITORS OF HIV-1 REVERSE TRANSCRIPTASE | PFIZER LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
| EP-1208091-B1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LTD (GB) | 2006-05-03 | — | — | EP | disclosed |
| CN-1213038-C | Benzophenones as reverse transcriptase inhibitors | GLAXO GROUP LTD (GB) | 2005-08-03 | — | — | CN | disclosed |
| CN-1636985-A | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| CN-1636986-A | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| CN-1636984-A | Benzophenones as inhibitors of reverse transcriptase | GLAXO GROUP LTD (GB) | 2005-07-13 | — | — | CN | disclosed |
| CN-1391565-A | Benzophenones as reverse transcriptase inhibitors | GLAXO GROUP LTD (GB) | 2003-01-15 | — | — | CN | disclosed |
| EP-1208091-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001017982-A1 | BENZOPHENONES AS INHIBITORS OF REVERSE TRANSCRIPTASE | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264425-A1 | CHEMICAL COMPOUNDS | POLR2E, POLR2A, POLRMT | CA12 4239/4885CA1 3764/4885CA2 3248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.